Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECVAX-NEO1 with PD-1/PD-L1 inhibitors in solid tumors
NCT06631079Phase 2Active, not recruiting
- Sponsor
- NEC Bio B.V.
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of NECVAX-NEO1 in solid tumor, sponsored by NEC Bio B.V. Primary endpoints: Adverse Events at 24 months, Serious Adverse Events at 24 months and 2 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
NECVAX-NEO1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06631079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631079.